Belatacept

Drug Profile

Belatacept

Alternative Names: BMS-224818; CTLA4-IgLEA29Y; LEA 29Y; Nulojix

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Emory University
  • Class Drug conjugates; Immunoconjugates; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen inhibitors; CD80 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Discontinued Liver transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2018 University of Maryland and Bristol-Myers Squibb completes a clinical trial for Renal transplant rejection (Prevention) in USA (NCT01496417)
  • 27 Jan 2017 Bristol-Myers Squibb completes a phase I pharmacokinetics trial in Healthy volunteers in USA (NCT02564497)
  • 01 Dec 2016 Bristol-Myers Squibb completes a phase II trial in Renal transplant rejection (Prevention, In adolescents) in USA (NCT01791491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top